-$0.23 EPS Expected for Nuvectis Pharma, Inc. (NASDAQ:NVCT) This Quarter

Equities research analysts forecast that Nuvectis Pharma, Inc. (NASDAQ:NVCTGet Rating) will report earnings of ($0.23) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Nuvectis Pharma’s earnings. The lowest EPS estimate is ($0.24) and the highest is ($0.22). The company is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Nuvectis Pharma will report full-year earnings of ($1.01) per share for the current year, with EPS estimates ranging from ($1.12) to ($0.89). For the next year, analysts expect that the business will post earnings of ($1.21) per share, with EPS estimates ranging from ($1.47) to ($0.95). Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Nuvectis Pharma.

A number of analysts have commented on NVCT shares. HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of Nuvectis Pharma in a report on Wednesday, April 13th. Roth Capital reissued a “buy” rating on shares of Nuvectis Pharma in a report on Sunday, April 17th.

NVCT traded up $0.46 during midday trading on Friday, hitting $9.50. The company had a trading volume of 9,496 shares, compared to its average volume of 85,438. Nuvectis Pharma has a 52 week low of $3.08 and a 52 week high of $11.04. The stock’s 50 day simple moving average is $8.20.

In other Nuvectis Pharma news, CEO Ron Bentsur bought 4,000 shares of Nuvectis Pharma stock in a transaction dated Monday, March 28th. The stock was bought at an average cost of $7.05 per share, with a total value of $28,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have acquired a total of 19,000 shares of company stock valued at $128,650 over the last three months.

About Nuvectis Pharma (Get Rating)

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases.

Recommended Stories

Get a free copy of the Zacks research report on Nuvectis Pharma (NVCT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.